Details for Patent: 7,772,209

Which drugs does patent 7,772,209 protect, and when does it expire?

Patent 7,772,209 protects PEMFEXY and ALIMTA and is included in two NDAs.

Protection for ALIMTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has eighteen patent family members in eleven countries.

Summary for Patent: 7,772,209

Title:	Antifolate combination therapies
Abstract:	A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent.
Inventor(s):	Niyikiza; Clet (Indianapolis, IN)
Assignee:	Eli Lilly and Company (Indianapolis, IN)
Application Number:	11/776,329
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,772,209
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 7,772,209

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eagle Pharms	PEMFEXY	pemetrexed	SOLUTION;INTRAVENOUS	209472-001	Feb 8, 2020		RX	Yes	Yes						USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH MESOTHELIOMA
Eagle Pharms	PEMFEXY	pemetrexed	SOLUTION;INTRAVENOUS	209472-001	Feb 8, 2020		RX	Yes	Yes						USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Lilly	ALIMTA	pemetrexed disodium	POWDER;INTRAVENOUS	021462-002	Sep 7, 2007	AP	RX	Yes	Yes
Lilly	ALIMTA	pemetrexed disodium	POWDER;INTRAVENOUS	021462-001	Feb 4, 2004	AP	RX	Yes	Yes

International Family Members for US Patent 7,772,209

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	359823
Australia	6968801
Cyprus	1107649
Germany	60127970
Denmark	1313508
European Patent Office	1313508